[go: up one dir, main page]

HUE036537T2 - ECM kompozíció, tumor-mikrokörnyezet platform és ezekhez eljárások - Google Patents

ECM kompozíció, tumor-mikrokörnyezet platform és ezekhez eljárások

Info

Publication number
HUE036537T2
HUE036537T2 HUE12838648A HUE12838648A HUE036537T2 HU E036537 T2 HUE036537 T2 HU E036537T2 HU E12838648 A HUE12838648 A HU E12838648A HU E12838648 A HUE12838648 A HU E12838648A HU E036537 T2 HUE036537 T2 HU E036537T2
Authority
HU
Hungary
Prior art keywords
methods
tumor microenvironment
ecm composition
microenvironment platform
platform
Prior art date
Application number
HUE12838648A
Other languages
English (en)
Inventor
Mallikarjun Sundaram
Biswanath Majumder
Misti Jain
Saravanan Thiagarajan
Dency Pinto
Padhma Radhakrishnan
Original Assignee
Mitra Rxdx India Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitra Rxdx India Private Ltd filed Critical Mitra Rxdx India Private Ltd
Publication of HUE036537T2 publication Critical patent/HUE036537T2/hu

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00Use of cells in diagnostics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/90Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE12838648A 2011-10-04 2012-10-04 ECM kompozíció, tumor-mikrokörnyezet platform és ezekhez eljárások HUE036537T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3310CH2011 2011-10-04

Publications (1)

Publication Number Publication Date
HUE036537T2 true HUE036537T2 (hu) 2018-07-30

Family

ID=54261176

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12838648A HUE036537T2 (hu) 2011-10-04 2012-10-04 ECM kompozíció, tumor-mikrokörnyezet platform és ezekhez eljárások

Country Status (14)

Country Link
US (7) US20140228246A1 (hu)
EP (1) EP2764099B1 (hu)
JP (2) JP6147259B2 (hu)
AU (1) AU2012320088C1 (hu)
CA (1) CA2850274A1 (hu)
CY (1) CY1120087T1 (hu)
DK (1) DK2764099T3 (hu)
ES (1) ES2660975T3 (hu)
HU (1) HUE036537T2 (hu)
NO (1) NO2764099T3 (hu)
PT (1) PT2764099T (hu)
SG (1) SG11201401183UA (hu)
TR (1) TR201802420T4 (hu)
WO (1) WO2013050962A1 (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105593438B (zh) 2013-05-31 2019-07-05 伊顿智能动力有限公司 用于通过平衡保护来降低动臂跳动的液压系统及方法
EP3074028B1 (en) * 2013-11-27 2022-04-06 Research Foundation Of The City University Of New York Activity enhancing curcumin compositions and methods of use
CN103966168B (zh) * 2014-05-19 2017-05-03 广州恒迪生物科技有限公司 肿瘤活组织体外培养系统及培养方法
US10745667B2 (en) 2015-03-23 2020-08-18 Yao Tang Methods of primary tissue culture and drug screening using autologous serum and fluids
JP6135795B2 (ja) * 2015-04-22 2017-05-31 小野薬品工業株式会社 リード化合物の抽出方法、創薬ターゲットの選択方法及び散布図生成装置並びにデータの可視化方法及び可視化装置
GB201507894D0 (en) * 2015-05-08 2015-06-24 Imagen Biotech Ltd Personalised media
CN108138146A (zh) 2015-10-20 2018-06-08 凯尔科迪公司 制备原代细胞样品的方法
CN106047788A (zh) * 2016-08-22 2016-10-26 上海逍鹏生物科技有限公司 一种适用于高密度细胞培养体系的培养基
GB2555787A (en) * 2016-11-07 2018-05-16 Landberg Goran Diagnostic methods
WO2018148334A1 (en) * 2017-02-08 2018-08-16 Mitra Rxdx, Inc. Method of predicting clinical outcome of anticancer agents
JP7616798B2 (ja) 2017-04-05 2025-01-17 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド エクスビボ培養系およびその使用方法
IL257225A (en) 2018-01-29 2018-04-09 Yeda Res & Dev Treatment of sarcoma
WO2019164951A1 (en) * 2018-02-22 2019-08-29 Mitra Rxdx, Inc. Methods of predicting response to temporally sequenced combination therapy
GB201818885D0 (en) 2018-11-20 2019-01-02 Precomb Therapeutics Ag 3d human cancer model-based combinatiorial drug development method
WO2020172591A1 (en) * 2019-02-22 2020-08-27 Mitra Rxdx, Inc. A method to predict a patient's response to an anti-cancer drug from an expression level of a set of genes
WO2020191105A2 (en) * 2019-03-19 2020-09-24 Kyuson Yun Methods and systems for evaluation of cell samples
CN112961830A (zh) * 2021-02-25 2021-06-15 重庆医科大学附属口腔医院 口腔鳞癌组织脱细胞基质及其制备方法和应用
CA3219233A1 (en) 2021-06-06 2022-12-15 Ravid STRAUSSMAN Combined treatment for cancer
CN113774025B (zh) * 2021-08-26 2023-07-14 湖南丰晖生物科技有限公司 一种结直肠癌顺铂耐药株的构建方法
WO2023067582A1 (en) * 2021-10-23 2023-04-27 Mazumdar Shaw Medical Foundation Tumor microenvironment platform comprising oral carcinoma for predicting drug sensitivity, drug resistance and disease progression
US12312631B1 (en) 2022-06-15 2025-05-27 SageMedic Corporation High-throughput multiplexed sensitivity and resistance assay
PL444462A1 (pl) * 2023-04-18 2024-10-21 Uniwersytet Medyczny W Białymstoku Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508188A (en) * 1994-01-21 1996-04-16 The Regents Of The University Of California Method of growing cells in a mammal
FR2842822B1 (fr) * 2002-07-26 2004-10-01 Roussy Inst Gustave Procede de preparation d'une matrice extracellulaire et son utilisation pour la culture de cellules tumorales
US8071135B2 (en) * 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
WO2010120329A1 (en) * 2009-04-15 2010-10-21 The University Of Medicine And Dentistry Of New Jersey Reconstituted tumor microenvironment for anticancer drug development
WO2011148669A1 (ja) * 2010-05-25 2011-12-01 株式会社 島津製作所 大腸がんマーカービトロネクチン、及び採血試料中のビトロネクチン濃度の分析方法

Also Published As

Publication number Publication date
EP2764099A1 (en) 2014-08-13
SG11201401183UA (en) 2014-09-26
ES2660975T3 (es) 2018-03-26
CY1120087T1 (el) 2018-12-12
AU2012320088B9 (en) 2015-07-16
WO2013050962A1 (en) 2013-04-11
AU2012320088C1 (en) 2016-03-17
US20190383795A1 (en) 2019-12-19
EP2764099B1 (en) 2017-11-22
US20190346428A1 (en) 2019-11-14
TR201802420T4 (tr) 2018-03-21
US20200064333A1 (en) 2020-02-27
EP2764099A4 (en) 2015-05-06
CA2850274A1 (en) 2013-04-11
JP6147259B2 (ja) 2017-06-14
JP6378273B2 (ja) 2018-08-22
US20140228246A1 (en) 2014-08-14
US20190353640A1 (en) 2019-11-21
AU2012320088B2 (en) 2015-07-02
US20190383796A1 (en) 2019-12-19
NO2764099T3 (hu) 2018-04-21
US20190170730A1 (en) 2019-06-06
DK2764099T3 (en) 2018-02-26
JP2014534809A (ja) 2014-12-25
AU2012320088A1 (en) 2014-05-01
PT2764099T (pt) 2018-02-28
JP2017061448A (ja) 2017-03-30

Similar Documents

Publication Publication Date Title
SG11201401183UA (en) Ecm composition, tumor microenvironment platform and methods thereof
IL269804A (en) Conjugates of an active protein material and a method for their preparation
IL253870A0 (en) Certain amino-pyrimidines, their assemblies, and methods of using them
IL222465A0 (en) Certain amino-pyridazines, compositions thereof, and methods for their use
ZA201208578B (en) Composition,method and use
PL2707224T3 (pl) Kompozycje polimerowe i sposoby
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
IL232213B (en) Antibody Formulations and Methods
LT2729151T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
GB201122195D0 (en) Composition and method
IL228557A0 (en) Solar absorbing formulations and related devices and methods
GB201408236D0 (en) Composition and method
GB201106433D0 (en) Composition and method
IL223436A (en) Methods for preparing tetranor - pgdm and tetranor - pgjm
GB201112426D0 (en) Composition and method
GB201102040D0 (en) Composition and method
GB201111496D0 (en) Composition and method
GB201116421D0 (en) Composition and method
GB201117620D0 (en) Method and composition
ZA201304786B (en) Analgesic compounds,methods,and formulations
PT3539540T (pt) Inibidor de sglt2 1-cloro-4-(beta-d-glucopiranos-1-il)-2-[4-((s)-tetra-hidrofurano-3-iloxi)-benzil]-benzeno em combinação com insulina para utilização num método para redução do risco de hipoglicemia